Last10K.com

Healthcare Trust Of America Holdings, Lp (1495491) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

1495491 Quarterly Reports

Healthcare Trust Of America Holdings, Lp

CIK: 1495491

Exhibit 99.1
bestinclasslogoa17a.jpg
PRESS RELEASE
Financial Contact:
Robert A. Milligan
Chief Financial Officer
480.998.3478

HEALTHCARE TRUST OF AMERICA, INC. REPORTS 2021 RESULTS AND ANNOUNCES FIRST QUARTER DIVIDEND

Scottsdale, Arizona (February 28, 2022) - Healthcare Trust of America, Inc. (NYSE: HTA) (“HTA”) announced results for the quarter and year ended December 31, 2021.
Fourth Quarter 2021 Highlights:
Reported net income attributable to common stockholders of $0.07 per diluted share.
Reported Funds From Operations (“FFO”), as defined by NAREIT, of $0.42 per diluted share.
Reported Normalized FFO of $0.43 per diluted share. This excludes $3.3 million of normalizing adjustments consisting of legal costs related to the whistleblower investigation of $1.7 million, CEO search fees of $0.7 million, legal and professional fees related to review of strategic alternatives of $0.4 million, and additional board and consulting fees pertaining to these matters of $0.5 million.
Reported Normalized FAD of $79.2 million, a decrease of 1.4% compared to Q4 2020.
Reported Same-Property Cash Net Operating Income (“NOI”) growth of 1.1% compared to Q4 2020. The change in Same-Property Cash NOI from Q4 2020 to Q4 2021 was impacted primarily by an additional $0.8 million of termination fees and late fees recognized in Q4 2020 as well as additional compensation costs of $0.3 million in the current period primarily related to employee retention matters.

Year Ended 2021:
Reported net income attributable to common stockholders of $98.0 million, or $0.44 per diluted share.
Reported FFO of $1.72 per diluted share, an increase of 10.3% compared to 2020.
Reported Normalized FFO of $1.75 per diluted share, an increase of 2.3% compared to 2020. This excludes the $3.3 million of normalizing adjustments mentioned above. Costs incurred in Q3 2021 pertaining to these matters were not significant and therefore were not included as normalizing adjustments for the year ended December 31, 2021.
Reported Normalized FAD of $326.7 million, an increase of 2.8% compared to 2020.
Raised our quarterly dividend for the 8th consecutive year.

Noteworthy Q4 2021 Matters:
The results for the three months ended December 31, 2021 were significantly impacted by several non-routine activities that resulted in additional costs totaling approximately $5.8 million, split between general and administrative and operating expenses. These items primarily related to the Company’s: (i) whistleblower investigation (as further outlined in the Company’s Current Report on Form 8-K filed November 4, 2021), (ii) CEO search costs, (iii) the announced strategic review process, and (iv) employee retention costs and administrative costs with respect to having an interim CEO. Costs related to these matters primarily included: (i) an increase in compensation and employee expenses including $1.2 million of increased bonus accruals related to Company out-performance on total shareholder return in Q3 2021, $0.7 million of CEO search fees, and $0.5 million of short-term consulting and other employee retention costs; (ii) increased legal and professional fees of $2.3 million primarily related to ongoing whistleblower and strategic review matters; (iii) increased corporate-related travel costs of $0.5 million; and (iv) increased board fees of $0.6 million as a result of a significant increase in board and committee meetings pertaining to the CEO search and whistleblower and strategic review matters, as well as additional compensation for the board chairman.
Additional costs incurred during Q3 2021 with respect to these non-routine activities were not significant. Accordingly, the results for the year ended December 31, 2021 were impacted primarily as a result of additional costs incurred during Q4 2021.
As noted above, of these additional costs, $3.3 million of expenses were identified as non-recurring or incremental in nature and has therefore been excluded from Normalized FFO as normalizing adjustments for the three months and year ended December 31, 2021.






The following information was filed by Healthcare Trust Of America Holdings, Lp on Monday, February 28, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Healthcare Trust Of America Holdings, Lp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Healthcare Trust Of America Holdings, Lp.

Continue

Assess how Healthcare Trust Of America Holdings, Lp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Healthcare Trust Of America Holdings, Lp's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Cover Page
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Changes In Partners' Capital
Condensed Consolidated Statements Of Changes In Partners' Capital (Parenthetical)
Condensed Consolidated Statements Of Comprehensive Income (Loss)
Condensed Consolidated Statements Of Equity
Condensed Consolidated Statements Of Equity (Parenthetical)
Condensed Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (Details)
Debt
Debt (Tables)
Debt - Amortization Of Deferred Financing Costs (Details)
Debt - Narrative (Details)
Debt - Principal Maturity Schedule (Details)
Debt - Schedule Of Debt (Details)
Derivative Financial Instruments And Hedging Activities
Derivative Financial Instruments And Hedging Activities (Tables)
Derivative Financial Instruments And Hedging Activities - Derivative Instruments Fair Value Table (Details)
Dispositions And Impairment
Dispositions And Impairment (Details)
Fair Value Of Financial Instruments
Fair Value Of Financial Instruments (Tables)
Fair Value Of Financial Instruments - Assets And Liabilities Measured On Recurring Basis (Details)
Fair Value Of Financial Instruments - Assets Measured On Non-Recurring Basis (Details)
Intangible Assets And Liabilities
Intangible Assets And Liabilities (Tables)
Intangible Assets And Liabilities - Summary Of Intangible Amortization (Details)
Intangible Assets And Liabilities - Summary Of Intangible Assets And Liabilities (Details)
Investments In Real Estate
Investments In Real Estate (Tables)
Investments In Real Estate - Acquisitions (Details)
Investments In Real Estate - Purchase Price Allocation (Details)
Investments In Real Estate - Weighted Average Lives (Details)
Leases
Leases (Tables)
Leases - Lease Revenues And Maturity Of Future Minimum Rents (Details)
Leases - Maturity Of Lease Liabilities (Details)
Leases - Narrative (Details)
Organization And Description Of Business
Organization And Description Of Business (Details)
Per Share Data Of Hta
Per Share Data Of Hta (Details)
Per Share Data Of Hta (Tables)
Per Unit Data Of Htalp
Per Unit Data Of Htalp (Details)
Per Unit Data Of Htalp (Tables)
Receivables And Other Assets
Receivables And Other Assets (Tables)
Receivables And Other Assets - Amortization (Details)
Receivables And Other Assets - Schedule Of Receivables And Other Assets (Details)
Stockholders' Equity And Partners' Capital
Stockholders' Equity And Partners' Capital (Tables)
Stockholders' Equity And Partners' Capital - Narrative (Details)
Stockholders' Equity And Partners' Capital - Restricted Common Stock Activity (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Narrative (Details)
Summary Of Significant Accounting Policies - Schedule Of Notes Receivable (Details)
Supplemental Cash Flow Information
Supplemental Cash Flow Information (Details)
Supplemental Cash Flow Information (Tables)
CIK: 1495491
Form Type: 10-Q Quarterly Report
Accession Number: 0001360604-22-000031
Submitted to the SEC: Fri May 06 2022 7:17:52 PM EST
Accepted by the SEC: Mon May 09 2022
Period: Thursday, March 31, 2022
Industry: Real Estate Investment Trusts

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1495491/0001360604-22-000031.htm